

Substitute for form 1449/PTO

Date Submitted: October 1, 2007

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/576,575
Filing Date	April 20, 2006
First Named Inventor	Robyn Lynne Ward
Art Unit	1634
Examiner Name	Unknown
Attorney Docket Number	037775-0107

[illegible]

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	A7	WO 01/75172 A2	10-11-2001	University of Southern California		
	A8	WO 2005/001141 A3	01-06-2005	Epigenomics AG		

Date
Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 1, 2007 <i>(use as many sheets as necessary)</i>		Application Number	10/576,575
		Filing Date	April 20, 2006
		First Named Inventor	Robyn Lynne Ward
		Art Unit	1634
		Examiner Name	Unknown
		Attorney Docket Number	037775-0107
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A9	ISSA et al.; "Accelerated Age-related CpG Island Methylation in Ulcerative Colitis ¹ ," Cancer Research, Vol. 61, No. 9, May 1, 2001; pp. 3573-3577	
	A10	HIBI et al.; "A Cancer-prone Case with a Background of Methylation of <i>p16</i> Tumor Suppressor Gene," Clinical Cancer Research; Vol. 9, No. 3; March 1, 2003; pp. 1053-1056	
	A11	WONG et al.; "Quantitative Analysis of Tumor-derived Methylated <i>P161NK4a</i> Sequences in Plasma, Serum, and Blood Cells of Hepatocellular Carcinoma Patients ¹ ," Clinical Cancer Research; Vol. 9, No. 3, March 2003; pp. 1047-1052;	
	A12	WIDSCHWENDTER et al.; "The Potential Prognostic, Predictive, and Therapeutic Values of DNA Methylation in Cancer ¹ ," Clinical Cancer Research; An Official Journal of the American Association for Cancer Research; Vol. 8, No. 1, January 2002; pp. 17-21	
	A13	HARDEN et al.; "Molecular assessment of histologically negative lymph nodes and correlation with survival in surgically resected stage I lung cancer using promoter methylation of multiple genes," Proceedings of the American Association for Cancer Research Annual Meeting; Vol. 43; March 2002; page 221	
	A14	ESTELLER et al.; "Analysis of <i>Adenomatous Polyposis Coli</i> Promoter Hypermethylation in Human Cancer ¹ ," Cancer Research, American Association for Cancer Research; Vol. 60, No. 16; August 15, 2000; pp. 4366-4371;	
	A15	GAZZOLI et al.; "A Hereditary Nonpolyposis Colorectal Carcinoma Case Associated with Hypermethylation of the <i>MLH1</i> Gene in Normal Tissue and Loss of Heterozygosity of the Unmethylated Allele in the Resulting Microsatellite Instability-High Tumor ¹ ," Cancer Research, Vol. 62, No. 14; July 15, 2002; pp. 3925-3928	
	A16	CUI et al.; "Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation of <i>H19</i> and <i>IGF2</i> ¹ ," Cancer Research, American Association for Cancer Research; Vol. 62; November 15, 2002; pp. 6442-6446	
	A17	SUTER et al.; "Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue," International Journal of Colorectal Disease, Springer Verlag, Berlin, DE, Vol. 19, No. 2, March 2004; pp. 95-101	
	A18	European Search Report (EP 04 78 9594); Date of Mailing: July 3, 2007; 6 pages	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.